ABSTRACT: There has been no study regarding the effect of a combination of teriparatide (TPTD) and zoledronic acid (ZA) on vertebral fusion. In this study, we investigate the effect of single and combined TPTD and ZA treatment on lumbar vertebral fusion in aged ovariectomized (OVX) rats. Sixty two-month-old female Sprague-Dawley rats were ovariectomized and underwent bilateral L4-L5 posterolateral intertransverse fusion after 10 months. The OVX rats received vehicle (control) treatment, or ZA (100 mg/kg, once), or TPTD (60 mg/kg/2 d for 42 d), or ZA þ TPTD until they were euthanized at 6 weeks following lumbar vertebral fusion. The lumbar spine was harvested. Bone mineral density (BMD), bone fusion, bone volume (BV), and bone formation rate (BFR)were analyzed by dualenergy X-ray absorptiometry (DXA), radiography, micro-computed tomography, and histomorphometry. Compared with vehicle (control) treatment, ZA and TPTD monotherapy increased bone volume (BV) at fusion site, and ZA þ TPTD combined therapy had an additive effect. Treatment with TPTD and ZA þ TPTD increased the bone fusion rate when compared with the control group. ZA monotherapy did not alter the rate of bone fusion. The TPTD and ZA þ TPTD treatment groups had increased mineral apposition rate (MAR), mineralizing surfaces/bone surface ((MS/BS), and BFR/BS compared with the OVX group. Our experiment confirm that the monotherapy with TPTD and combination therapy with ZA þ TPTD in an OVX rat model of osteopenia following lumbar vertebral fusion surgery increased bone fusion mass and bone fusion rate, and ZA þ TPTD combined therapy had an additive effect on bone fusion mass. ß
The most common surgical treatment for degenerative and traumatic spine disease is spinal fusion with bone grafting. This surgical procedure is performed to restore mechanical stability to the affected spinal segment by connecting bone between two or more vertebrae. Currently, the reported rates of non-union vary from 0% to 56% after spinal surgical procedures failing to produce vertebral fusion. 1 Osteoporosis is characterized by reduced bone mass and decreased bone mineral density (BMD) associated with the destruction of the bone microstructure, resulting in increased bone fragility, and susceptibility to fracture. Osteoporosis is also an important risk factor for the complication of vertebral non-union following spinal surgery. 2 Due to osteoporosis is one of the important reasons for non-union following surgical vertebral fusion surgery, there have been recent studies on the effects of anti-resorptive or anabolic drugs to inhibit bone graft resorption and promote fusion rates, including calcitonin, bisphosphonates (BPs), and teriparatide (TPTD). [3] [4] [5] [6] [7] [8] [9] [10] Zoledronic acid (ZA), one of the most potent BPs, and TPTD (PTH 1-34) are currently effective anti-resorptive and anabolic drugs respectively for the treatment of osteoporosis. [3] [4] [5] [6] [7] [8] [9] At present, published studies on the effects of BPs on vertebral fusion have produced conflicting results. For example, some animal studies have shown that there was no significant adverse effect of alendronate on fusion outcome 8, 9, 11 ; other preclinical studies have shown that alendronate inhibited spinal vertebral fusion. 6, 12 In 2007, Bransford et al. 4 showed a positive effect of ZA treatment on vertebral fusion in an L6-L7 rabbit vertebral fusion model. In 2012, we conducted a clinical study on the effects of ZA infusion in patients undergoing transforaminal lumbar interbody fusion surgery, which indicated that a clinical dose of ZA of 5 mg did not alter the fusion rate. 13 An animal study of the effect of ZA on lumbar vertebral fusion was conducted recently in our department, which showed that ZA in higher doses have a positive effect on vertebral fusion. 14 There have been some animal studies on the effects of TPTD on vertebral fusion, and almost all of these studies have reported a positive effect on vertebral fusion. 5, 7, 15, 16 In two recent clinical studies, 10, 17 the authors concluded that administration of TPTD might increase vertebral fusion rates of the patients with osteoporosis. However, another study showed that treatment with TPTD resulted in no significant improvement in the fusion rate. 18 In a recently published study, the effects of TPTD and ZA treatment were studied on fracture healing in ovariectomized (OVX) osteopenic rats. 19 The findings in this study suggested an additive effect of ZA and TPTD on fracture healing, and this additive effect was specific to the quantity of callus and not to undamaged bone tissue. 19 Also, ZA þ TPTD has been shown to have a stronger effect on fracture healing than either monotherapy in OVX rats. 20 At present, the effect of TPTD on vertebral bone fusion rates has been compared with that of BPs in only three clinical studies, 10, 17, 18 but there have been no previous studies on the effect of a combination of TPTD and ZA on vertebral fusion either in clinical or animal studies. Based on these previous studies, we wished to determine whether the combination of ZA and TPTD treatment could also have a positive effect on vertebral graft bone healing in a rat model of osteopenia.
The aim of the present study was to investigate the effect of combined ZA and TPTD treatment on lumbar vertebral fusion in an OVX rat model of osteopenia and to compare the effects of the monotherapy and combination therapy.
MATERIALS AND METHODS

Animals
Sixty two-month-old female Sprague-Dawley rats (body weight: 230-250 g) were used for the experiments and were provided by the Department of Laboratory Animal Science of Fudan University. The animals were maintained under controlled temperature at 24 AE 2˚C with 12 h dark/light cycle with unrestricted access to tap water and food. All the rats were anesthetized and then sacrificed by exsanguination from the abdominal aorta, than the whole lumbar spine was harvested for further analysis at the end of the study period. The experimental protocol was approved by the Experimental Animal Ethics Committee, Zhong shan hospital, Fudan University.
Chemicals
Zoledronic acid (ZA) monohydrate was purchased from Sigma-Aldrich (St. Louis, MO) and dissolved in saline to 100 mg/ml. The powder form of teriparatide (TPTD) was purchased from Bachem (Switzerland) and was dissolved in distilled water to 60 mg/ml.
Surgical Procedure
Anesthesia was induced by intraperitoneal injection of a mixture of ketamine (90 mg/kg) and diazepam (3 mg/kg). After the surgical site was shaved and cleaned, the rats were placed in a prone position, and the L4-L5 posterolateral intertransverse fusion was performed, as previously described. 14, 21, 22 Briefly, using the iliac crests as an anatomic landmark, a posterior single midline skin incision, and two paramedian fascial incisions were made over the lumbar spine. The transverse processes of the L4 and L5 lumbar vertebrae were exposed by splitting the back muscles. A high-speed electric burr was used to decorticate the cortical bone of the transverse processes until fine bleeding points were observed. About 0.25 g of autologous iliac bone was harvested from each iliac crest; the bone graft was morselized and placed bilaterally as a bridge between the decorticated L4 and L5 fusion beds. The fascial and skin incisions were closed using 3-0 sutures.
Experimental Design
Forty-eight rats were subjected to ovariectomy, and 12 rats received sham operations under general anesthesia with the mixture anesthetic agents previously described injected intraperitoneally. Ten months after ovariectomy or sham operation, all animals underwent the surgical procedure. Immediately post-operatively, All of the sham-operated rats entered the sham group and the ovariectomized animals were randomized by body weight into four groups (12 rats in each group): sham-operated control (Sham) group, ovariectomized (OVX) control group, OVX rats treated with 100 mg/kg ZA once post-operatively (ZA group), OVX rats treated with 60 mg/kg every second time(60 mg/kg/2d) TPTD for 42 d (TPTD group), and OVX rats treated with combined 100 mg/kg ZA once and 60 mg/kg /2d TPTD for 42 d (ZA þ TPTD group). ZA was administered as a single s.c. injection immediately after the spinal fusion procedure, while the sham, OVX, and ZA groups were injected subcutaneously with saline once every two d until the end of the study. Two fluorochromes, xylenol orange (90 mg/kg, Sigma-Aldrich) and tetracycline (25 mg/kg, Sigma-Aldrich) were respectively injected subcutaneously at 13 d (xylenol orange) and intramuscularly at 3 d (tetracycline) before rats were euthanized. All of the rats were euthanized after 42 days of treatment, and than the whole lumbar spine was harvested for further analysis.
Dual-Energy X-Ray Absorptiometry (DXA)
The BMD of the L2-L3 vertebrae, both distal femurs, and both iliac crests (pelvis) were measured using dual-energy X-ray absorptiometry (DXA) under ether inhalation anesthesia at 2, 6, and 10 months after ovariectomy or sham operation, to confirm the establishment of the osteopenic animal model. Furthermore, the L2-L3 vertebrae and bilateral distal femur BMD were measured before the rats were euthanized. Animals were placed in the prone position on the scanning table, and the whole body was scanned at a speed of 25 mm/min, and the BMD in regions of interest were obtained.
Manual Palpation
Immediately after death, the rat lumbar spines were harvested, and all surrounding soft tissues were cleaned. Two independent blinded observers manually palpated the harvested lumbar spines which in randomized order, and the lateral motion at the L4-L5 level was compared with that at the adjacent levels above (L3-L4) and below (L5-L6). Specimens were graded as fused, partially fused, or not fused.
14,23
X-Ray Assessment of Vertebral Fusion
Anteroposterior X-ray radiographs of specimens were taken under consistently controlled conditions (35 kV, 90 s). Two independent radiologists, who were blinded to the identity of the study groups, reviewed the radiographs, and the fusion grades were assessed based on previously published studies. 24 Grade A vertebral fusion was defined as a solid bilateral fusion mass; grade B was seen on the X-ray as a unilateral fusion mass; a small bilateral fusion mass was defined as grade C, and graft resorption was defined as grade D vertebral fusion.
Micro-Computed Tomography (Micro-CT) Analysis
All the lumbar spine specimens were scanned with the use of high-resolution micro-computed tomography (micro-CT)
(Quantum GX, Perkins-Elmer) under consistently controlled conditions (90 kV, 88 mA, 14 min, pixel size: 144 mm) to evaluate the fusion site. Areas of interest included the upper end of the L4 transverse process to the lower end of the L5 transverse process, including the fusion segment ( Fig. 1A-D) as previously described.
14 Bone volume (BV), and the percentage bone volume fraction: Bone volume /tissue volume (BV/TV) were analyzed on both the right and left sides with the use of imaging software (Analyze 12.0).
Histological Analysis
To evaluate bone formation activity and measure the newlyformed callus and bone, two fluorochromes, xylenol orange (90 mg/kg, Sigma-Aldrich) and tetracycline (25 mg/kg, Sigma-Aldrich), were injected subcutaneously at 13 d (xylenol orange) and intramuscularly at 3 d (tetracycline) before rats were euthanized. Undecalcified bone specimens were embedded in methyl methacrylate for sectioning. Thin sections (200-300 mm) were cut on a microtome (EXAKT, Germany) and then ground to a thickness of 20-30 mm, left unstained for analysis with a fluorescence microscope connected to a computer with a software (AxioVision SE64 Rel. 4.9). A region of interest in the fusion mass was investigated. The mineral apposition rate (MAR) was determined as the distance between the double labels divided by the interlabeling time. The mineralizing surfaces/bone surface (MS/BS) were calculated by double label surface plus half single surface then divided by total bone surface, and the bone formation rate (BFR) was calculated as MAR Â MS/ BS, as previously described. 25 All nomenclature for histomorphometry followed standard usage. 26 
Statistical Analysis
Differences in the manual palpation and radiographic data were analyzed using Kruskal-Wallis statistics and Mann-Whitney U tests. The significant differences between two independent measurements were considered to be p < 0.01 based on the Bonferroni correction of the pvalue. The other data were presented as mean AE standard deviation (SD). Comparison between groups was analyzed by one-way ANOVA followed by Bonferroni multiple comparison tests. And the differences were considered significant at p < 0.05. All statistical analysis was performed with IBM SPSS version 19 statistical software (Chicago, IL).
RESULTS
Animals
Two rats died during ovariectomy, one rat died during the sham operation; another five rats died during or shortly after the vertebral fusion surgery. Therefore, a total of 52 rats were used for the final analysis.
Bone Mineral Density (BMD)
Based on the dual-energy X-ray absorptiometry (DXA) analysis, for the bone mineral density (BMD) of the three regions (distal femur, lumbar spine, and pelvis), the animals in the ovariectomized (OVX) groups had significantly lower BMD (distal femur: 18.6%, p< 0.01; lumbar spine: 22.8%, p < 0.01; pelvis: 19.7%, p < 0.01) compared with the sham-operated group, 10 months after sham operation or ovariectomy (Fig. 2A) . Furthermore, the OVX groups had significantly lower femoral and lumbar spinal BMD at 10 months after ovariectomy than those at 6 months after ovariectomy (distal femur: 7.4%, p < 0.05; lumbar spine: 6.5%, p < 0.05; 10 vs. 6 months), but there was no significant change in the pelvic site (1.8%, p > 0.05), and the BMD showed no significant differences at all three sites between 2 and 6 months post-operatively in the OVX group (Fig. 2B-D) . These results indicated that the BMD of the animals in the OVX groups became more severe 10 months after ovariectomy.
It shows that at the endpoint of three treatment protocols after spinal fusion (Fig. 2E-F) , the BMD of the ZA, TPTD, and ZA þ TPTD groups at both the distal femur and lumbar spine sites increased after the drug therapy, and showed significant differences compared with those in OVX group before the fusion surgery (OVX-10-month) (p < 0.05). However, there were no significant differences among the drug treatment groups for the BMD in the distal femur or lumbar spine sites at the endpoint of the study, and the BMD of the OVX group had no significant changes before and 2 months after the fusion procedure. These findings indicated that treatment with ZA, TPTD, and ZA þ TPTD increased BMD compared with the OVX control group.
Vertebral Fusion Rate Analyzed by Manual Palpation
The numbers of fused, partially fused, and non-fused lumbar spines that were in the sham-operated group, which had no significant differences compared with the OVX control group (p ¼ 0.829) ( Table 1 ). There was no significant difference between the ZA and OVX control group (p ¼ 0.147). The fusion rate of the lumbar vertebrae in the TPTD and ZA þ TPTD groups showed 
Vertebral Fusion Rate Analyzed by X-Ray
The different results of the lumbar vertebral fusion as representative radiographs of the lumbar spine in all five groups, according to the result of the X-ray assessment (Fig. 3A) . The numbers of vertebral fusion grades A, B, C, or D did not differ significantly between the sham-operated and OVX control groups (p ¼ 0.394), or between the ZA and OVX control groups (p ¼ 0.043). Although the number of spines graded as a small bilateral fusion mass (grade C) in the OVX control group were relatively greater than that in the ZA group, the difference of fusion grades was not significant (p ¼ 0.043) ( Table 2 ). However, the fusion grades in the TPTD and ZA þ TPTD groups were improved compare to the OVX control group. The majority cases in the TPTD and ZA þ TPTD groups were graded as a solid bilateral and unilateral fusion mass, no cases of graft resorption were observed, and this difference was statistically significant (p ¼ 0.005 for TPTD vs. OVX; p ¼ 0.001 for ZA þ TPTD vs. OVX). However,
Figure 2. Bone mineral density (BMD) examined by dual-energy X-ray absorptiometry (DXA) after ovariectomy(A-D) or treatment (E-F). (A)
The ovariectomized (OVX) rat groups had significantly lower BMD at the distal femur, spine and pelvic sites compared with the sham-operated group, 10 months after sham operation, or ovariectomy 10-month. (B and C) The OVX groups had significantly lower femoral and lumbar spinal BMD at 10 months compared with 6 months after ovariectomy. (F) There was no significant change at 10 months in the pelvic BMD. (E and F) Treatment with the zoledronic acid (ZA), teriparatide (TPTD), and ZA þ TPTD significantly increased the BMD at both distal femur and lumbar vertebral sites compared with those in the ovariectomized (OVX) control group before the treatment start(OVX-10-month). Month 0 means when ovariectomy was performed. Data were expressed as mean AE SD (n ¼ 10 there was no significant difference among the three treatment groups.
Micro-Computed Tomography (Micro-CT)
The (Fig. 3B) . The result of the BV/TV was consistent with the BV in the OVX group; the BV/TV was significantly lower than in the sham-operated group, the ZA, TPTD and ZA þ TPTD groups. Whereas, among all the treatment groups, there were no significant differences (Fig. 3C ). These findings indicated that all the three drug regimens could promote bone healing to different degrees. Fig. 3D shows the 3D images of L4-L5 vertebral fusion, and shows the different sizes of the fusion mass.
Bone Histomorphometry
Histological sections of the lumbar vertebral fusion mass of the three different treatment groups showed increased fluorescence with xylenol orange (orange) and tetracycline (yellow) compared with the OVX control group (Fig. 4A-B) . Histological analysis showed that the mineral apposition rate (MAR) (11.5%, p > 0.05) was lower in the OVX control group than in the sham-operated group (Fig. 4C) . However, the difference was not significant, and there were no significant differences on MS/BS and bone formation rate (BFR) between these two groups ( Fig. 4D-E) . The TPTD and ZA þ TPTD groups had significantly higher MAR (TPTD: threefold increase, ZA þ TPTD: 3.2-fold increase), MS/BS (TPTD: 1.6-fold increase, ZA þ TPTD: twofold increase), BFR/BS (TPTD: 4.5-fold increase, ZA þ TPTD: 6.5-fold increase) compared with the OVX group. However, the ZA group only showed an increasing trend in the MAR, MS/BS, and BFR/BS, the differences were not significant. Significant differences were observed for MAR, MS/BS, and BFR/BS between ZA and ZA þ TPTD groups, and the MS/BS in the ZA þ TPTD group were significantly greater than the TPTD-treated groups.
DISCUSSION
The findings of this study showed that monotherapy and combination therapy with zoledronic acid (ZA) and teriparatide (TPTD) in an aged ovariectomized (OVX) rat model of osteopenia following lumbar vertebral fusion surgery increased bone fusion mass, and increased the osteopenia induced by ovariectomy. Additionally, the TPTD and TPTD þ ZA regimens increased the bone fusion rate.
In this study, we used an 12-month old OVX rat model 10 month after ovariectomy with more severe osteopenia than that in the established osteopenic animal model 2 month post-OVX. Clinically, bisphosphonates (BPs) are the first-line treatment for osteoporosis, while TPTD is approved for failure of BPs, or for severe osteoporosis. [27] [28] [29] Furthermore, it is possible that the 12-month-old rat could be a better model of human osteoporosis because the bone remodeling processes could prevail over bone modeling. 30 in clinical practices, most osteoporosis patients are aged postmenopausal women, age-related, and OVX induced decrease of BMD contribute simultaneously to the pathogenesis of osteoporosis. Therefore, an aged osteopenic animal model may better represent the clinical situation and may better evaluate the effect of monotherapy and combination therapy of ZA and TPTD.
In this study, ZA treatment increased the bone mineral density (BMD) in the distal femur and spine sites, as well as increasing the bone volume (BV) and the BV/TV in the fusion area. However, ZA treatment did not alter the fusion rate assessed by X-ray examination. These findings are supported by those from a former animal study from our center, 14 which found that ZA treatment at a clinical dose (100 mg/kg) did not significantly alter the bone fusion rate, but a higher dose of ZA increased the fusion rate. The BV and BV/TV of the bone fusion mass were increased significantly with increasing doses of ZA (from 20 to 500 mg/kg). The clinical dose of ZA demonstrated a trend of increasing the fusion rate, both in this study and in the former study from our laboratory, and the effect became more obvious when the dosage increased. The findings indicated that a higher dose of ZA might increase the fusion rate in the OVX rat. A further animal study showed that the BP, alendronate, increased the fusion mass in ovariectomized rats. 8 The treatment of the OVX rats with TPTD increased the BV and BV/TV in the lumbar vertebral fusion site when compared with the untreated group and significantly increased the fusion rate. In previous studies, TPTD has been shown to prevent bone loss induced by ovariectomy, 31, 32 which may be due to stimulation of osteoblast formation and an increase in osteoblast activity. 33 In 2016, Qiu et al. 15 suggested that intermittent TPTD treatment in osteoporosis increased the BV/TV and the formation of the cortical shell at the fusion site, and increased the mineral apposition rate (MAR). These changes also indicated the anabolic effect of TPTD in promoting new bone formation, as Qiu et al. 15 also used the OVX rat model. This previous study also supports our findings that the MAR and bone formation rate (BFR)/BS also increased in the TPTD-treated group.
In the present study, we also found that TPTD increased BMD at the femoral, vertebral, and pelvic sites, and had a greater effect on spinal fusion mass. Previous studies have shown that TPTD increased BMD at the skeletal site in an aged ovariectomized rat model 34 or immobilized rat model 20, 25, 35 and that the increased BMD in TPTD-treated animals was always accompanied by an increase in bone formation. Another previous study has suggested that the TPTD associated increase in BMD contributes to the increase in bone strength in the aged OVX rat model, and to the efficacy of TPTD treatment over standard BPs in increasing cancellous bone. 36 A further study on fracture healing have shown that mechanical strength correlated with cortical bone formation 37 and that TPTD also could enhance and accelerate cortical bone formation. 15 The dose of TPTD that we chose in this study was 60 mg/kg, which was based on earlier animal studies. 25, 38 Although the dose of TPTD used was relatively greater than the clinical dose, it showed a substantial anabolic effect in the osteopenic rat model.
The combination treatment of ZA plus TPTD had an additive effect on BV of the vertebral bone fusion mass. However, no further effect was seen in the fusion rate and the BMD in femoral and vertebral spinal bone for the combination treatment when compared with ZA or TPTD monotherapy. These findings were in accordance with a previously reported study that showed no additive effect on the undamaged bone site, but a strong effect on callus formation. 39 Through the combination therapy, the fusion mass was increased the most, this might be due to the inhibition of bone turnover which is associated with the anabolic activity of TPTD, as the osteoblast is the target cell of TPTD at the graft healing site. 40 However, Vegger et al. 20 did find an additive effect of TPTD and ZA in preserving undamaged bone mass at the distal femoral metaphysis in immobilized rats. This difference in findings may be due to the use of different animal models.
This study has some limitations. First, the physiological condition of humans is thought to be different from that of rats, like humans are bipedal and walk upright while rats are reptile, so our results are not completely applicable to graft bone healing in spinal fusion surgery in humans. Second, although ZA þ TPTD in this study produced stronger effects than either monotherapy on graft bone healing in OVX rat model of osteopenia following lumbar vertebral fusion surgery, the mechanisms of action has not been completely identified. Third, we used only one dose in the present study, however, Ming et al. 7 concluded that teriparatide has a dose-dependent effect in promoting spinal fusion in rats, and the most effective dose of teriparatide use for spinal fusion was still not clear in preclinical or clinical studies. Aforementioned points remain to be established in the future study.
In conclusion, monotherapy with TPTD and combination therapy with ZA þ TPTD in an OVX rat model of osteopenia following lumbar vertebral fusion surgery increased bone fusion mass and bone fusion rate, and the combination treatment had an additive effect on bone fusion mass whereas a clinical dose of ZA monotherapy did not alter the bone fusion rate.
